Feb 27, 2026 06:20AM
Jan 21, 2026 11:45AM
Jan 13, 2026 12:19PM
Nov 7, 2025 08:50AM
Nov 7, 2025 08:42AM
Sep 19, 2025 07:59AM
Jul 24, 2025 01:42PM Ipsen wins EU approval for Cabometyx in neuroendocrine tumors
Jul 24, 2025 01:41PM
Jun 20, 2025 06:19AM
May 6, 2025 01:30AM
Apr 24, 2025 02:14AM
Sep 23, 2024 07:13AM
Jul 26, 2024 06:46AM
Jun 10, 2024 04:54PM Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Jun 7, 2024 01:00AM
May 2, 2024 01:30AM
Apr 24, 2024 01:00AM
Feb 13, 2024 04:08PM
Dec 7, 2023 01:00AM
Nov 13, 2023 07:00AM
Oct 23, 2023 01:00AM Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
Sep 4, 2023 01:00AM
Sep 1, 2023 01:00AM
Aug 16, 2023 03:32PM
Jul 21, 2023 08:52AM
Jul 21, 2023 07:52AM
Jul 19, 2023 12:42PM
Jun 28, 2023 08:00PM Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
Jun 14, 2023 04:35PM
Jun 14, 2023 02:21PM
Jun 13, 2023 01:10PM
Jun 12, 2023 01:00AM
May 26, 2023 08:20AM
Apr 27, 2023 01:00AM
Apr 24, 2023 02:00AM Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs
Mar 16, 2023 02:02PM
Mar 2, 2023 02:13PM
Feb 15, 2023 01:00AM
Feb 13, 2023 05:00PM
Feb 9, 2023 01:00AM
Jan 27, 2023 01:00AM
Jan 20, 2023 10:00AM Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
Jan 9, 2023 04:52AM
Jan 9, 2023 01:00AM
Dec 23, 2022 05:00PM
Dec 8, 2022 04:05PM
Nov 9, 2022 06:57AM
Nov 9, 2022 01:01AM
Oct 27, 2022 12:57AM Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
Oct 25, 2022 10:20AM

1,168,522 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All